Severe Fingolimod Rebound Syndrome After Switching To Cladribine Treatment
We present the clinical and imaging characteristics of a patient whom presented with rebound syndrome after switching from fingolimod to cladribine treatment due to hematologic toxicity. Previous imaging studies had shown a non-aggressive phenotype of the disease, however multiple active tumefactive lesions became evident after beginning treatment with cladribine. The patient responded well to plasmapheresis. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - January 16, 2020 Category: Neurology Source Type: research

Emergence of Rheumatoid Arthritis Following Exposure to Natalizumab
We report a patient with relapsing-remitting multiple sclerosis, who developed rheumatoid arthritis after exposure to natalizumab. While some multiple sclerosis therapies are known to unmask autoimmune conditions, natalizumab is rarely implicated as a cause of alternative autoimmunity. This case illustrates an unusual clinical scenario which may support recent scientific work suggesting that when natalizumab blocks T helper 1 cells from entering the central nervous system, T helper 17 cells may continue to migrate into immune-privileged spaces and cause pathologic inflammation.Brief Background: Multiple sclerosis (MS) pati...
Source: Multiple Sclerosis and Related Disorders - January 16, 2020 Category: Neurology Source Type: research

Evaluation of Ethnicity as a Predictor of Diagnostic Phenotype and Prognosis in Neuromyelitis Optica Spectrum Disorder in Toronto, Canada
ConclusionsIn this multi-ethnic cohort from Toronto, Canada, blacks with NMOSD were less likely than Asians to demonstrate classic NMO by 2006 diagnostic criteria. Caucasians had better long-term disability outcomes compared to Asians as measured by the EDSS. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - January 16, 2020 Category: Neurology Source Type: research

A Case of Combined Central and Peripheral Demyelination in Zambia
We present a case of a 32-year-old man who was found to have both clinically isolated syndrome and chronic inflammatory demyelinating polyneuropathy, highlighting the importance of continued efforts to establish the prevalence of demyelinating disease in the region given the limited treatment options currently available for autoimmune disease. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - January 16, 2020 Category: Neurology Source Type: research

Neurobrucellosis Presenting as Longitudinally Extensive Transverse Myelitis: A Case Report and Review of the Literature
Publication date: Available online 13 January 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): B.I. Yamout, J. Massouh, I. Hushaymi, M. Zeineddine, G. Saab (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - January 15, 2020 Category: Neurology Source Type: research

Drug-induced liver injury associated with the biosimilar glatiramer acetate (Clift®)
Publication date: Available online 13 January 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Sebastian Michels, Eugen Zizer, Thomas FE Barth, Anette Wassner, Tanja Fangerau, Daniela Taranu, Franziska Bachhuber, Hayrettin Tumani, Makbule SenelAbstractA 23-year old female was diagnosed with relapsing-remitting multiple sclerosis with two symptomatic attacks. Immunomodulatory treatment with Clift® (Glatiramer Acetate biosimilar) was initiated. Shortly after administration, an asymptomatic increase in liver enzymes was noticed, and therapy was paused. However, we observed an enormous increase in liver enzym...
Source: Multiple Sclerosis and Related Disorders - January 15, 2020 Category: Neurology Source Type: research

Comparison of Health-Related Quality of Life Across Treatment Groups in Individuals with Multiple Sclerosis
ConclusionWe examined differences between MS treatment groups across a wide range of HRQOL outcomes. The results suggest that overall there are few differences between treatments on the physical, cognitive and emotional dimensions of well-being. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - January 12, 2020 Category: Neurology Source Type: research

Reliability and Validity of a novel device for quantifying ankle dorsiflexion force in Persons with Multiple Sclerosis
ConclusionThe ROQ-TA is a valid and highly reliable device to test dorsiflexion force in PwMS. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - January 12, 2020 Category: Neurology Source Type: research

Concurrence of Multiple Sclerosis, Oligodendroglioma, and Autosomal Recessive Cerebellar Ataxia with Spasticity in the Same Patient: A Challenging Diagnosis
Publication date: Available online 11 January 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Hussein Algahtani, Bader Shirah, Mohamed Tashkandi, Alaa SamkariAbstractMultiple sclerosis (MS) has been described in several case reports to coexist with brain tumors. This unusual concurrence has been the subject of research projects with a common question of whether these pathological entities share common roots. However, no clear association has proved that either of them could provoke the other, and mere chance is the only acceptable explanation. Along all reported cases, oligodendroglioma has been rarely repor...
Source: Multiple Sclerosis and Related Disorders - January 11, 2020 Category: Neurology Source Type: research

Maternal micro-chimeric cells in the multiple sclerosis brain
This study shows that female cells presumed to be MMC are a common phenomenon in adult human brain where they appear to have embedded into brain tissue with the ability to express tissue specific markers. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - January 10, 2020 Category: Neurology Source Type: research

Physical Activity and Peak Oxygen Consumption are Associated with Walking in Multiple Sclerosis
Publication date: Available online 9 January 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Brooks A. Hibner, Thessa I.M. Hilgenkamp, Elizabeth C. Schroeder, Robert W. Motl, Rachel E. Bollaert, Garett Griffith, Georgios Grigoriadis, Tracy Baynard, Bo FernhallAbstractIntroductionMultiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system with a prevalence of nearly 1 million adults in the United States. MS results in declines in physical activity and peak oxygen consumption that might be independently associated with declines in walking performance. Therefore our purpose was to ev...
Source: Multiple Sclerosis and Related Disorders - January 10, 2020 Category: Neurology Source Type: research

Refining cell-based assay to detect MOG-IgG in patients with central nervous system inflammatory diseases.
Conclusion: We have developed MOG-IgG CBAs that have different characteristics and benefits but with high specificity and concordance. The complementary use of two methods and follow-up study with larger cohort will increase the clinical usefulness of MOG-IgG CBAs. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - January 9, 2020 Category: Neurology Source Type: research

“No Evidence of Disease Activity”: Is it an Aspirational Therapeutic Goal in Multiple Sclerosis?
Publication date: Available online 9 January 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Mayssam El Najjar, Cynthia Eid, Samia Khoury, Salem HannounAbstract‘No evidence of disease activity’ (NEDA) that has been identified as a potential outcome measure for the evaluation of DMTs effects. The concept has been adopted from other diseases such as cancer where treatment is intended to free the patient from the disease. Disease-free status has been substituted by NEDA in MS, since we are limited when it comes to fully evaluating the underlying disease. In general, NEDA, otherwise termed as NEDA-3,...
Source: Multiple Sclerosis and Related Disorders - January 9, 2020 Category: Neurology Source Type: research

Under-treated depression negatively impacts lifestyle behaviors, participation and health-related quality of life among older people with multiple sclerosis
Conclusion: Undiagnosed and under-treated depression is common among older people living with MS and adversely impacts health choices. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - January 9, 2020 Category: Neurology Source Type: research

The role of the clinical nurse specialist multiple sclerosis, the patients’ and families’ and carers’ perspective: An integrative review
Conclusion: It can be argued that MS CNSs are best placed to meet the complex, variable needs individuals with MS, their families and carers. Further evidence is required to explore the variability of the disease and the progressive effect and impact of cognitive decline on MS patient, families’ and carers’ in order to meet their fluctuating and often complex needs. Findings from the review suggest a multifaceted role, and additionally, the needs of patients, families and carers are difficult to define as they vary over time as the disease progresses. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - January 9, 2020 Category: Neurology Source Type: research

Do Secondary Progressive Multiple Sclerosis patients benefit from Computer- based cognitive neurorehabilitation? A randomized sham controlled trial
Publication date: Available online 7 January 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Lambros Messinis, Mary H Kosmidis, Grigorios Nasios, Spyridon Konitsiotis, Aikaterini Ntoskou, Christos Bakirtzis, Nikolaos Grigoriadis, Panayiotis Patrikelis, Elias Panagiotopoulos, Philippos Gourzis, Sonia Malefaki, Panagiotis PapathanasopoulosABSTRACTBackgroundCognitive impairment is common in multiple sclerosis (MS), but deficits tend to be more pronounced in progressive MS, negatively impacting daily functional capacity. Despite this, most cognitive rehabilitation (CR) interventions to date have focused on relap...
Source: Multiple Sclerosis and Related Disorders - January 7, 2020 Category: Neurology Source Type: research

Socioeconomic deprivation increases the risk of disability in Multiple Sclerosis patients
Conclusions: In this study, socioeconomic deprivation was significantly associated to the disability risk in MS patients. Better knowledge of socioeconomic disparities in MS may help adapt care to settings and improve the quality of care given to patients in the future.Graphical Abstract (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - January 7, 2020 Category: Neurology Source Type: research

Amyloid PET findings in multiple sclerosis are associated with cognitive decline at 18 months
ConclusionsLower white matter uptake in amyloid PET is associated with cognitive decline and an increase in white matter lesion volume during the follow-up. Our study suggests that 18F-florbetaben may be a useful biomarker in assessing myelin status in MS, understanding MS pathophysiology, and predicting cognitive outcomes. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - January 7, 2020 Category: Neurology Source Type: research

A long-term follow-up of rituximab treatment in 20 Chinese patients with neuromyelitis optica spectrum disorders
ConclusionsWe confirmed the long-term efficacy and safety of low-dose rituximab in adult Chinese patients with NMOSD. We recommend monitoring of B cell repopulation to instruct individualised regimens for patients with NMOSD in clinical practice. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - January 6, 2020 Category: Neurology Source Type: research

Do clinical trials for new disease modifying treatments include real world patients with multiple sclerosis?
Conclusion: We did not observe significant differences in most clinical and demographic aspects of included patients in RCT and RWS. Studies that include the full spectrum of MS patients followed in clinical practice are needed (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - January 4, 2020 Category: Neurology Source Type: research

Cryptococcus neoformans var grubii meningoencephalitis in a patient on fingolimod for relapsing-remitting multiple sclerosis: case report and review of published cases
Conclusion: We suggest consideration of harm minimisation behaviours in patients requiring fingolimod, particularly in those with profound CD4 lymphopenia. Furthermore, we echo the call for improved post-marketing surveillance systems to determine the epidemiology of atypical infections with novel immunomodulatory treatments. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - January 4, 2020 Category: Neurology Source Type: research

Autoimmune glial fibrillary acidic protein astrocytopathy resulting in treatment-refractory flaccid paralysis
We report a case of autoimmune GFAP astrocytopathy with the unusual feature of radiculoneuritis in addition to encephalomyelitis, resulting in flaccid paralysis unresponsive to immunotherapy. Imaging data confirmed involvement of brain, spinal cord and nerve roots. Electrodiagnostic testing showed changes consistent with a severe sensorimotor neuropathy with active denervation. The results of this case suggest the need for future studies to assess the impact of peripheral nerve involvement on the outcome in autoimmune GFAP astrocytopathy. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - January 4, 2020 Category: Neurology Source Type: research

Title: The Role of the Clinical Nurse Specialist Multiple Sclerosis, the patients’ and families’ and carers’ perspective: an integrative review
Conclusion: It can be argued that MS CNSs are best placed to meet the complex, variable needs individuals with MS, their families and carers. Further evidence is required to explore the variability of the disease and the progressive effect and impact of cognitive decline on MS patient, families’ and carers’ in order to meet their fluctuating and often complex needs. Findings from the review suggest a multifaceted role, and additionally, the needs of patients, families and carers are difficult to define as they vary over time as the disease progresses. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - January 4, 2020 Category: Neurology Source Type: research

Rebound of disease activity after fingolimod withdrawal: immunological and gene expression profiling
We present the clinico-radiological and immunological description of a case of rebound activity after fingolimod discontinuation and switching to rituximab treatment in a relapsing-remitting MS patient. After severe rebound, a reduction in the expression of inflammatory cytokines and transcription factors was rapidly observed after administration of methylprednisolone and rituximab. Rituximab led to an effective suppression of inflammatory activity, and at least in this specific case it represented a valid switching approach after fingolimod discontinuation. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - January 4, 2020 Category: Neurology Source Type: research

Amyloid PET findings in multiple sclerosis are associated with cognitive decline at 18 months.
CONCLUSIONSLower white matter uptake in amyloid PET is associated with cognitive decline and an increase in white matter lesion volume during the follow-up. Our study suggests that 18F-florbetaben may be a useful biomarker in assessing myelin status in MS, understanding MS pathophysiology, and predicting cognitive outcomes. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - January 3, 2020 Category: Neurology Source Type: research

Predictive Medicine in Multiple Sclerosis: a Systematic Review
ConclusionsOverall, there is a lack of validated predictive tools in MS, and further external validation of the existing ones are required. Demonstration of the clinical usefulness is also needed prior to being transferred into clinical practice. Finally, our study illustrates that the MS literature needs to integrate good standards in developing and validating predictive models. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - January 3, 2020 Category: Neurology Source Type: research

Patient needs and preferences in relapsing-remitting multiple sclerosis: a systematic review
ConclusionsUnderstanding the needs and preferences of CIS/RRMS patients regarding DMT attributes and non-treatment related attributes are important to improve treatment decision-making and reduce non-adherence. Studies are needed to understand patient preferences upon treatment initiation. Furthermore, preference studies should include attributes based on the patient perspective. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - January 3, 2020 Category: Neurology Source Type: research

Autoimmune glial fibillary acidic protein astrocytopathy associated meningoencephalomyelitis and bilateral sensorineuronal deafness
Publication date: Available online 31 December 2019Source: Multiple Sclerosis and Related DisordersAuthor(s): Bonaventure Ip, Crystal Lam, Vincent Ip, Anne Chan, Vincent Mok, Elaine Au, Eric Chan, Alexander LauAbstractAutoimmune encephalitis is an important group of disease that can mimic infectious encephalitis, with one of the most severe forms being meningoencephalomyelitis. One of the recently identified biomarkers, glial fibillary acidic protein (GFAP), targets the cytosolic intermediate filament protein of astrocytes and causes a variety of clinical symptoms. Here, we report an adult Chinese woman presented with acut...
Source: Multiple Sclerosis and Related Disorders - January 1, 2020 Category: Neurology Source Type: research

To treat or not to treat: Sequential individualized treatment evaluation in relapsing multiple sclerosis
Conclusion: Apart from the doubtless substantial improvement of the overall prognosis of RMS by DMT, it seems likely that not every patient necessarily needs immediate or even “hard and early” treatment. A “watchful waiting” approach with continuous clinical evaluation might be instead a viable option in RMS patients with favorable prognostic features at onset. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - December 31, 2019 Category: Neurology Source Type: research

Is diet associated with physical capacity and fatigue in persons with multiple sclerosis? –Results from a pilot study
Conclusion: Although not consistent across analyses, these findings suggest that better physical capacity most often is associated with a diet rich in carbohydrates and reduced fat content. Further research and randomized controlled trials are required to fully assess the role and the efficacy of diet quality and content on physical capacity in PwMS. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - December 30, 2019 Category: Neurology Source Type: research

Effectiveness of Subcutaneous Tocilizumab in Neuromyelitis Optica spectrum disorders
Conclusions: Effectiveness of subcutaneous TCZ in NMOSD appears to be similar to that reported for the IV formulation and has an advantage of at-home administration. Prospective, comparative studies of subcutaneous TCZ for NMOSD are warranted. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - December 30, 2019 Category: Neurology Source Type: research

Validation of 0–10 MS symptom scores in the Australian multiple sclerosis longitudinal study
ConclusionThe six assessed symptoms of the MSSymS performed equally well compared to validated comparison measures in terms of concurrent and predictive validity, temporal stability and responsiveness. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - December 27, 2019 Category: Neurology Source Type: research

Tacrolimus is effective for neuromyelitis optica spectrum disorders with or without anti-AQP4 antibody
In this study, we retrospectively investigated the disorder relapse-suppressing effect of tacrolimus (TAC) when combined with prednisolone (PSL) in anti-AQP4 antibody-positive and -negative NMOSD cases.Methods: Subjects were NMOSD outpatients treated at our hospital in August 2016 who fulfilled the 2015 International Panel for NMO Diagnosis criteria and whose medical history before visiting our department was known; anti-myelin oligodendrocyte glycoprotein antibody-positive cases were excluded. We retrospectively investigated the annualized relapse rate (ARR) before and after combined TAC and PSL treatment in 50 NMOSD case...
Source: Multiple Sclerosis and Related Disorders - December 27, 2019 Category: Neurology Source Type: research

Pediatric Optic Neuritis and anti MOG antibodies: a cohort of Italian patients
Publication date: Available online 24 December 2019Source: Multiple Sclerosis and Related DisordersAuthor(s): Thea Giacomini, Thomas Foiadelli, Pietro Annovazzi, Margherita Nosadini, Matteo Gastaldi, Diego Franciotta, Claudio Panarese, Paolo Capris, Paola Camicione, Paola Lanteri, Elisa De Grandis, Giulia Prato, Ramona Cordani, Lino Nobili, Giovanni Morana, Andrea Rossi, Angela Pistorio, Maria Cellerino, Antonio Uccelli, Stefano SartoriAbstractBackground: recent studies reported that anti myelin oligodendrocyte glycoprotein (MOG) antibody(ab)related optic neuritis (ON)tend to have characteristics that differ from seronegat...
Source: Multiple Sclerosis and Related Disorders - December 25, 2019 Category: Neurology Source Type: research

To treat or not to treat – sequential individualized treatment evaluation in relapsing multiple sclerosis
Conclusion: Apart from the doubtless substantial improvement of the overall prognosis of RMS by DMT, it seems likely that not every patient necessarily needs immediate or even “hard and early” treatment. A “watchful waiting” approach with continuous clinical evaluation might be instead a viable option in RMS patients with favorable prognostic features at onset. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - December 24, 2019 Category: Neurology Source Type: research

Neuro-Behcet's Disease: An Update on Diagnosis, Differential Diagnoses, and Treatment
Publication date: Available online 23 December 2019Source: Multiple Sclerosis and Related DisordersAuthor(s): Afshin Borhani-Haghighi, Bahareh Kardeh, Shubhasree Banerjee, Golnaz Yadollahikhales, Anahid Safari, Mohammadali Sahraian, Lee ShapiroAbstractNeuro-Behcet's disease (NBD) is defined as a combination of neurologic symptoms and/or signs in a patient with Behcet's disease (BD). Relevant syndromes include brainstem syndrome, multiple-sclerosis like presentations, movement disorders, meningoencephalitic syndrome, myelopathic syndrome, cerebral venous sinus thrombosis (CVST), and intracranial hypertension. Central nervou...
Source: Multiple Sclerosis and Related Disorders - December 24, 2019 Category: Neurology Source Type: research

Objective sensor-based gait measures reflect motor impairment in multiple sclerosis patients: reliability and clinical validation of a wearable sensor device
Conclusion: Sensor-based gait analysis objectively supports the clinical assessment of gait abnormalities even in the lower stages of MS, especially when walking with fast speed. Stride length and gait speed where identified as the most clinically relevant gait measures. Thus, it may be used to support the assessment of PwMS with gait impairment in the future, e.g. for more objective classification of disability. Its role in home-monitoring scenarios need to be evaluated in further studies. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - December 24, 2019 Category: Neurology Source Type: research

Relative importance of vision and proprioception in maintaining standing balance in people with multiple sclerosis
Conclusions: Like healthy individuals, persons with MS rely more on proprioception to maintain body balance than vision. Our findings could provide preliminary reference for optimizing balance improving programs aimed at person with MS. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - December 21, 2019 Category: Neurology Source Type: research

Photoreceptor Outer Nuclear layer Thickness Changes in Optic Neuritis Follow up
In this study, we determine longitudinal changes in retinal layer thickness in ON.Methods: Thirty ON patients underwent optical coherence tomography (OCT) and visual function testing at baseline, one month, and 6 months.Results: Mean GCIPL thickness decreased at one month relative to baseline from 63.6 ± 7.5 μm to 57.3 ± 6.8 µm in 3 mm ring (P
Source: Multiple Sclerosis and Related Disorders - December 21, 2019 Category: Neurology Source Type: research

Correlations of health status indicators with perceived neuropsychological impairment and cognitive processing speed in multiple sclerosis.
Conclusion: Increasing age is associated with reduced cognitive processing speed whereas comorbidities and sleep behaviors contribute to subjective cognitive performance. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - December 21, 2019 Category: Neurology Source Type: research

Comparison of the effects of two different exergaming systems on balance, functionality, fatigue, and quality of life in people with multiple sclerosis: A randomized controlled trial
ConclusionIn comparison with no intervention, exergaming with Nintendo Wii Fit and Balance Trainer improves balance, increases functionality, reduces fatigue severity, and increases quality of life in PwMS. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - December 21, 2019 Category: Neurology Source Type: research

The impact of modifiable risk factors on lesion burden in patients with early multiple sclerosis
ConclusionsSeveral risk factors may play a role in evolution of MS. Our results show that smoking status, probably due to chronic vascular and neurotoxic effects of the cigarette components, can affect the brain damage from the early stages of MS. No association was observed with the other explored modifiable risk factors, although an effect due to the small sample size cannot be excluded. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - December 21, 2019 Category: Neurology Source Type: research

A case of GFAP-astroglial autoimmunity presenting with reversible parkinsonism
Publication date: Available online 19 December 2019Source: Multiple Sclerosis and Related DisordersAuthor(s): Anna Tomczak, Elaine Su, Madina Tugizova, Aaron M. Carlson, Lucas B. Kipp, Haojun Feng, May H. HanAbstractAutoimmune glial fibrillary acidic protein (GFAP) astrocytopathy is a newly recognized autoimmune central nervous system (CNS) inflammatory disorder, presenting with an array of neurological symptoms in association with autoantibodies against GFAP, a hallmark protein expressed on astrocytes. Limited knowledge is available on the disease pathogenesis and clinical outcome. Here, we report a case of autoimmune GFA...
Source: Multiple Sclerosis and Related Disorders - December 21, 2019 Category: Neurology Source Type: research

Low CSF β-amyloid levels predict early regional grey matter atrophy in multiple sclerosis
Conclusions: CSF Aβ levels seem to be crucial in MS early brain volume loss as GM atrophy manifests in regions particularly vulnerable to early Aβ deposition. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - December 21, 2019 Category: Neurology Source Type: research

Validation of 0-10 MS Symptom Scores in the Australian Multiple Sclerosis Longitudinal Study
Conclusion: The six assessed symptoms of the MSSymS performed equally well compared to validated comparison measures in terms of concurrent and predictive validity, temporal stability and responsiveness. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - December 18, 2019 Category: Neurology Source Type: research

Thalamo-cortical dysfunction contributes to fatigability in multiple sclerosis patients: a neurophysiological study
Conclusions: HFOs, a neurophysiological marker of thalamo-cortical pathway, are significantly modified by fatiguing tasks in MS patients, in particular the early component that refers to the functionality of thalamic axons. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - December 17, 2019 Category: Neurology Source Type: research

Prevalence of self-reported language impairment in multiple sclerosis and the association with health-related quality of life: An international survey study
The objectives of this study were to identify the prevalence and nature of self-reported language impairment in MS using a validated MS-specific patient-reported outcome measure and to determine the association with health-related quality of life (HRQoL) and demographic and clinical variables.MethodsIn this cross-sectional study, 160 persons with MS completed the language items of the Speech pathology-specific questionnaire for persons with MS (SMS) to assess language and the 12-Item Short Form Survey (SF-12) to assess HRQoL. Participants were recruited internationally through professional MS bodies and support groups and ...
Source: Multiple Sclerosis and Related Disorders - December 17, 2019 Category: Neurology Source Type: research

Effectiveness of glatiramer acetate in neutralizing antibody-positive patients previously treated with interferon-β.
Conclusion: While on GA, patients switched from IFNβ in the context of disease activity and no NAbs had the highest risk of future disease activity, while NAb positive patients without previous activity had the lowest. We did not find any average difference between NAb-positive patients switching in a context of disease activity and NAb-negative patients switched due to adverse events, although carefulness in the interpretation of this result is advised. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - December 16, 2019 Category: Neurology Source Type: research

Disease activity impacts disability progression in primary progressive multiple sclerosis
ConclusionOlder age at onset and presence of clinical and/or radiological disease activity correlated with accelerated disability progression in this cohort of PPMS patients. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - December 15, 2019 Category: Neurology Source Type: research

Long-term real-world evidence for sustained clinical benefits of fingolimod following switch from natalizumab
Conclusions: In patients discontinuing natalizumab, fingolimod has a favorable benefit–risk profile over 48 months. These findings also suggest using a short washout following natalizumab discontinuation, consistent with guidelines and current clinical practice in Germany. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - December 13, 2019 Category: Neurology Source Type: research